BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 16571654)

  • 1. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
    Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
    Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2.
    Marcu J; Shore DM; Kapur A; Trznadel M; Makriyannis A; Reggio PH; Abood ME
    J Pharmacol Exp Ther; 2013 May; 345(2):189-97. PubMed ID: 23426954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
    Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
    J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
    Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
    Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
    McCollum L; Howlett AC; Mukhopadhyay S
    J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
    Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
    Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
    Sim-Selley LJ; Martin BR
    J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
    McMahon LR
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis.
    Köfalvi A; Rodrigues RJ; Ledent C; Mackie K; Vizi ES; Cunha RA; Sperlágh B
    J Neurosci; 2005 Mar; 25(11):2874-84. PubMed ID: 15772347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study.
    Petitet F; Jeantaud B; Capet M; Doble A
    Biochem Pharmacol; 1997 Dec; 54(11):1267-70. PubMed ID: 9416978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a sphingosine 1-phosphate receptor antagonist prodrug.
    Kennedy PC; Zhu R; Huang T; Tomsig JL; Mathews TP; David M; Peyruchaud O; Macdonald TL; Lynch KR
    J Pharmacol Exp Ther; 2011 Sep; 338(3):879-89. PubMed ID: 21632869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.
    Landsman RS; Burkey TH; Consroe P; Roeske WR; Yamamura HI
    Eur J Pharmacol; 1997 Sep; 334(1):R1-2. PubMed ID: 9346339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.
    Shoemaker JL; Joseph BK; Ruckle MB; Mayeux PR; Prather PL
    J Pharmacol Exp Ther; 2005 Aug; 314(2):868-75. PubMed ID: 15901805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effects of SR141716A on G-protein activation in rat brain.
    Sim-Selley LJ; Brunk LK; Selley DE
    Eur J Pharmacol; 2001 Mar; 414(2-3):135-43. PubMed ID: 11239913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats.
    Zaniewska M; McCreary AC; Przegaliński E; Filip M
    Eur J Pharmacol; 2006 Jul; 540(1-3):96-106. PubMed ID: 16730696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.
    Rinaldi-Carmona M; Barth F; Congy C; Martinez S; Oustric D; Pério A; Poncelet M; Maruani J; Arnone M; Finance O; Soubrié P; Le Fur G
    J Pharmacol Exp Ther; 2004 Sep; 310(3):905-14. PubMed ID: 15131245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
    Meschler JP; Kraichely DM; Wilken GH; Howlett AC
    Biochem Pharmacol; 2000 Nov; 60(9):1315-23. PubMed ID: 11008125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
    Darmani NA; Janoyan JJ; Crim J; Ramirez J
    Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system.
    Griffin G; Wray EJ; Tao Q; McAllister SD; Rorrer WK; Aung MM; Martin BR; Abood ME
    Eur J Pharmacol; 1999 Jul; 377(1):117-25. PubMed ID: 10448934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
    Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG
    Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.